New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
06:36 EDTSHPG, C, NPSPShire secures $5B credit facility for NPS Pharma bid, Times of London says
Shire (SHPG) has secured a $5B credit facility led by Citigroup (C) for a takeover offer for NPS Pharmaceuticals (NPSP), The Times of London reports. According to insiders, an initial approach by Shire to NPS was rebuffed. Reference Link
News For SHPG;NPSP;C From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
March 23, 2015
09:45 EDTSHPGUBS to hold a field trip
Subscribe for More Information
09:44 EDTCCiti fires two over inflation trading error, Bloomberg says
Subscribe for More Information
09:37 EDTSHPGActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL AUY SLB PFE MCP CELG VRTX SHPG GILD LOGI TSLA TASR NFLX SCTY WFM
08:53 EDTCAmazon VP and General Manager of Payments departs, TechCrunch says
Subscribe for More Information
07:36 EDTSHPGPfizer should rise 'significantly' over next two years, says Jefferies
Jefferies analyst Jeffrey Holford told investors this morning that he expects shares of Pfizer (PFE) to appreciate "significantly" over the next two years. A survey of U.S. oncologists indicated the company's Ibrance drug will be used in 50% of first line hormonal therapy within one year, with off-label use in all lines of therapy including adjuvant, Holford noted. He thinks peak sales of the drug could top $13B, which is well above consensus. In addition, the analyst views Pfizer's Global Established Pharmaceutical business as being underappreciated by the market. Potential value creating options for the pharmaceutical giant include spinning off its GEP unit by 2017 and accretive acquisitions, with possible takeover targets being Shire (SHPG), Actavis (ACT), AstraZeneca (AZN) and GlaxoSmithKline (GSK), in the eyes of Holford. He added the stock to the firm's Franchise Picks list, which encompasses its best ideas. He also raised his price target for Pfizer to $45 from $42. The stock closed Friday up 10c to $34.25.
07:19 EDTCCapital Link to hold a forum
Subscribe for More Information
March 22, 2015
18:05 EDTCCitigroup authorized to process Argentine bond payments, Reuters says
Subscribe for More Information
17:10 EDTCCiti shares could rise faster, Barron's says
Citi shares have remained relatively flat and shares could rise a little faster as the company continue to improve, Barron's argues in a follow up article. Reference Link
March 20, 2015
16:00 EDTCOptions Update; March 20, 2015
Subscribe for More Information
10:00 EDTSHPGOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:41 EDTSHPGBernstein global specialty pharma analyst holds analyst/industry conference call
Subscribe for More Information
08:12 EDTSHPGShire upgraded to Outperform from Market Perform at Bernstein
Bernstein upgraded Shire as the firm thinks that the stock's risk/reward ratio is positive following several new developments. Among these developments are the firm's belief that the company's orphan drug strategy looks increasingly strong, while the risks to the company's Vyvanse and mesalamines drugs look to have moderated and the company has several near-term, 2015 catalysts. Target $295.
March 19, 2015
16:01 EDTCOptions Update; March 19, 2015
Subscribe for More Information
11:53 EDTCU.S. banks face headwinds in unloading oil loans, WSJ says
Subscribe for More Information
09:06 EDTCCiti Retail Services extends long term consumer relationship with Office Depot
Subscribe for More Information
07:15 EDTCCiti CEO tells shareholders 2015 targets 'within reach,' Reuters reports
Subscribe for More Information
06:06 EDTCCiti files lawsuit over Swiss franc surge, Reuters says
Subscribe for More Information
March 18, 2015
13:56 EDTCArgentina to bar Citi from exiting custody business, Reuters says
Subscribe for More Information
08:03 EDTSHPGTherapeuticsMD names Angus Russell, J. Martin Carroll as directors
TherapeuticsMD (TXMD) announced the appointment of two biopharmaceutical senior executives, Angus C. Russell and J. Martin Carroll, as independent members of its board of directors, and that Randall S. Stanicky has stepped down from the board of directors. Angus C. Russell served as CEO of Shire PLC (SHPG) from June 2008 until April 2013. J. Martin Carroll served as president and CEO of Boehringer Ingelheim Corp. U.S. from 2003 until 2011.
07:22 EDTSHPGShire looking for 'transformational' deal, Betaville blog says
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use